Biosplice Therapeutics: Developing First-in-Class, Small-Molecule Therapeutics

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Biosplice Therapeutics.

Biotechnology has a wide array of applications impacting our daily lives. It contributes significantly to developing food products, medications, agricultural products, and more, using genetically modified organisms and clinical trials. The biotechnology industry is revolutionizing and growing, with numerous startups making big impacts in different fields, especially biopharmaceutical.

One such globally recognized startup is Biosplice Therapeutics. It has transformed into the world’s most valuable US-based startup by researching and developing medicinal drugs for osteoarthritis, oncology, neurology, and other degenerative conditions.

Let’s dig in to uncover more about Biosplice Therapeutics.

Biosplice Therapeutics – Company Highlights

About Biosplice Therapeutics
Biosplice Therapeutics – Industry
Biosplice Therapeutics – Founders and Team
Biosplice Therapeutics – Startup Story
Biosplice Therapeutics – Mission and Vision
Biosplice Therapeutics – Business Model
Biosplice Therapeutics – Revenue Model
Biosplice Therapeutics – Products and Services
Biosplice Therapeutics – Challenges Faced
Biosplice Therapeutics – Funding and Investors
Biosplice Therapeutics – Growth
Biosplice Therapeutics – Partners
Biosplice Therapeutics – Competitors

About Biosplice Therapeutics

Biosplice Therapeutics is a clinical-stage biotechnology company that develops first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing for major diseases.

The California-based company is focused on osteoarthritis and oncology, along with early-stage programs in neurology and other areas of significant unmet medical need. It discovers new targets and biological processes in the Wnt pathway to develop small-molecule drugs that potentially address multiple degenerative conditions.

Biosplice Therapeutics – Industry

Biosplice Therapeutics operates in the Biotechnology industry, the global market size of which was approximately $1.22 trillion in 2022 and is projected to reach $3.21 trillion by 2030, with a remarkable CAGR of 12.8% during the forecasted period. With the rise of the biotechnology sector in developing countries like India, China, and Japan, the market is growing rapidly due to favorable government initiatives.

Additionally, during the Covid-19 pandemic, the need for discovering novel solutions to develop vaccines and diagnostic tools to combat the disease increased. Some prominent companies capturing a significant share of the biotechnology industry are AstraZeneca, Gilead Sciences, Inc., Bristol-Myers Squibb, Sanofi, and Biogen.

Biosplice Therapeutics – Founders and Team

Osman Kibar is the founder of Biosplice Therapeutics.

Osman Kibar

Osman Kibar is the founder and Executive Chairman of Biosplice Therapeutics. He earned his B.S. in Electrical Engineering from Caltech and a B.A. in Mathematics and Economics from Pomona College. Moreover, he completed his M.S. and Ph.D. in Biophotonics and Optoelectronics from U.C. San Diego. Osman is an entrepreneur and inventor who founded multiple successful companies, including Genoptix, Dynamic Connections, and E-Tenna.

Cevdet Samikoglu

Cevdet Samikoglu is the CEO of Biosplice Therapeutics. He earned a B.A. in Economics from Hamilton College and completed MBD from Harvard Business School. Cevdet is the ex-Director of Research at Goldman Sachs and ex-Co-founder and Co-Portfolio Manager at Greywolf Capital Management. Before appointing Biosplice Therapeutics' CEO, he worked as CFO and President at the company.

Biosplice Therapeutics Team

• Cevdet Samikoglu – Chief Executive Officer
• Yusuf Yazici – Chief Medical Officer
• Erich Horsley – Chief Financial Officer
• Scott W. Bulcao – Chief Legal Officer

Biosplice Therapeutics is a team of 120+ employees.

Biosplice Therapeutics – Startup Story

Biosplice Therapeutics was founded by Osman Kibar in 2008. Osman moved to San Diego in 2008 and incorporated the biotechnology company named Wintherix. He later rebranded the company as Samumed.

The company made quite the entrance in 2016 with a $220 million war fund, a pipeline of anti-aging pharmaceuticals, and a whopping valuation of nearly $12 billion in 2018. Furthermore, it quietly changed its name to Biosplice Therapeutics in 2021 after adding another $120 million to its coffers.

Biosplice Therapeutics enrolled for a Phase II clinical trial for Osteoarthritis treatment of the Knee in 2015 and successfully completed it in 2017. Moreover, the company completed a Phase I Study for Potential Idiopathic Pulmonary Fibrosis Treatment in 2017. It was in 2020 that Biosplice Therapeutics announced the publication of Phase 2 data on Lorecivivint. It initiated the New Phase 3 Trial for Knee Osteoarthritis in 2022. Additionally, the firm announced new clinical data for Cirtuvivint at the European Society for Medical Oncology Meeting in September 2022.

Biosplice Therapeutics – Mission and Vision

Biosplice Therapeutics aims to restore healthy by delivering first-in-class therapies harnessing alternative splicing.

Biosplice Therapeutics – Business Model

Biosplice Therapeutics' scientific platform is based on biological discoveries governing tissue specialization, enabling the company to selectively eliminate harmful proteins using small molecules. Its foundational discoveries in Wnt pathway modulation unlocked the broad therapeutic potential of alternative splicing by targeting the CLK/DYRK family kinases. These kinases govern the selection of tissue-specific and disease-selective mRNA splice sites, making them attractive, druggable targets within the cellular command and control centers.

Biosplice Therapeutics – Revenue Model

Biosplice Therapeutics makes money by developing and launching regenerative medicines for articular cartilage damage, degenerative disc disease, lung tissue regeneration, osteoarthritis, oncology, neurology, and other degenerative conditions.

Benchling: A Biotechnology Research and Development Platform

A cloud-based bioinformatics platform, Benchling delivers innovative solutions for biotechnology research and development.

Ayushi GoyalStartupTalky

Biosplice Therapeutics – Products and Services

Biosplice Therapeutics clinical developments include:

• Cirtuvivint for numerous cancers
• Lorecivivint for osteoarthritis (in Phase 3)
• A broad pipeline ranging from Alzheimer’s disease to other degenerative conditions

Biosplice Therapeutics – Challenges Faced

In February 2022, Biosplice Therapeutics laid off nearly a quarter of its employees and culled a male pattern baldness drug from its pipeline.

A few months later, in November 2022, the company announced that its bid to transform the treatment of arthritis into cancer ran into a snag with its experimental osteoarthritis drug failing to benefit patients in a pair of Phase 3 clinical trials.

Biosplice Therapeutics – Funding and Investors

Biosplice Therapeutics has undertaken 5 funding rounds and raised a total of $778 million. Its latest funding round – Venture Series Unknown Round, was completed on April 15, 2021, and raised a total of $120 million. Recent investors who backed Biosplice Therapeutics include Eventide Asset Management, SymBiosis II, aMoon, Verition Fund Management, Sands Capital, and many others.

Biosplice Therapeutics – Growth

Biosplice Therapeutics witnessed a whopping increase in its valuation from $6 billion in 2016 to $12.8 billion in 2018.

Biosplice Therapeutics – Partners

Biosplice Therapeutics has partnered with:

• Epic Sciences
• Haisco Pharmaceutical Group Co., Ltd.

Biosplice Therapeutics – Competitors

Some main competitors of Biosplice Therapeutics are as follows:

• Chordia Therapeutics
• Twist Bioscience
• Hopewell Therapeutics
• Lycia Therapeutics
• Edogena Therapeutics
• Bionaut Labs

FAQs

What does Biosplice Therapeutics do?

Biosplice Therapeutics is a clinical-stage biotechnology company that develops first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing for major diseases.

Who is the founder of Biosplice Therapeutics?

Biosplice Therapeutics was founded by Osman Kibar in 2008.

Who are the main competitors of Biosplice Therapeutics?

The main competitors of Biosplice Therapeutics are Chordia Therapeutics, Twist Bioscience, Hopewell Therapeutics, Lycia Therapeutics, Edogena Therapeutics, and Bionaut Labs.